Table 1. Concordance between TST, T-SPOT.TB and QFT-GIT results stratified by study visit and BCG vaccination status.
| Time-point | Assay (n = 166) | Agreement | |||||
| TST | T-SPOT.TB (Day 0) | QFT-GIT (Day 0) | |||||
| % | κ (95% CI) | % | κ (95% CI) | % | κ (95% CI) | ||
| Day 0 Baseline | T-SPOT.TB (all) | 91.0 | 0.62 (0.44–0.79) | ||||
| T-SPOT.TB (BCG-naive) | 90.2 | 0.73 (0.53–0.93) | |||||
| T-SPOT.TB (BCG-vaccinated) | 91.4 | 0.44 (0.14–0.73) | |||||
| QFT-GIT (all) | 89.8 | 0.37 (0.14–0.60) | 90.4 | 0.46 (0.25–0.67) | |||
| QFT-GIT (BCG-naive) | 82.0 | 0.40 (0.15–0.66) | |||||
| QFT-GIT (BCG-vaccinated) | 94.3 | 0.22 (−0.18–0.63) | |||||
| Day 7 Post-TST | T-SPOT.TB (all) | 91.0 | 0.62 (0.44–0.79) | 91.6 | 0.66 (0.50–0.83) | 93.4 | 0.73 (0.58–0.88) |
| T-SPOT.TB (BCG-naive) | 91.8 | 0.78 (0.60–0.96) | |||||
| T-SPOT.TB (BCG-vaccinated) | 90.5 | 0.33 (0.02–0.64) | |||||
| QFT-GIT (all) | 91.6 | 0.63 (0.46–0.81) | 93.4 | 0.73 (0.58–0.88) | 91.0 | 0.48 (0.26–0.70) | |
| QFT-GIT (BCG-naive) | 91.8 | 0.78 (0.59–0.96) | |||||
| QFT-GIT (BCG-vaccinated) | 91.4 | 0.36 (0.04–0.68) | |||||
| Day 200 | T-SPOT.TB (all) | 89.8 | 0.57 (0.38–0.75) | 91.6 | 0.66 (0.50–0.83) | 88.6 | 0.51 (0.32–0.70) |
| T-SPOT.TB (BCG-naive) | 90.2 | 0.73 (0.53–0.93) | |||||
| T-SPOT.TB (BCG-vaccinated) | 89.5 | 0.31 (0.01–0.60) | |||||
| QFT-GIT (all) | 84.9 | 0.30 (0.10–0.51) | 88.6 | 0.51 (0.32–0.70) | 88.6 | 0.30 (0.07–0.52) | |
| QFT-GIT (BCG-naive) | 85.3 | 0.53 (0.29–0.78) | |||||
| QFT-GIT (BCG-vaccinated) | 84.8 | 0.05 (−0.16–0.25) | |||||
TST = tuberculin skin test; QFT-GIT = QuantiFERON Gold in-Tube; BCG = Bacillus Calmette-Guérin.